Murine cytomegalovirus infection leads to increased levels of transplant arteriosclerosis in a murine aortic allograft model

Transplantation

Volumn 90, Issue 4, 2010, Pages 373-379

  Heim, Christian ^a   Abele Ohl, Silke ^a   Eckl, Sebastian ^a   Ramsperger Gleixner, Martina ^a   Mahmoudian, Shohreh ^a   Weyand, Michael ^a   Stamminger, Thomas ^a   Ensminger, Stephan M ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Adhesion molecules; Dendritic cells; Murine cytomegalovirus; Transplant arteriosclerosis

Indexed keywords

CD62E ANTIGEN; CYCLOSPORIN; EVEROLIMUS; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 4; LYMPHOCYTE ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MESSENGER RNA; TACROLIMUS; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ABDOMINAL AORTA; ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA GRAFT; ARTERIOSCLEROSIS; ARTERY INTIMA PROLIFERATION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS INFECTION; DENDRITIC CELL; DONOR; GENE EXPRESSION; GRAFT RECIPIENT; GRAFT REJECTION; HISTOLOGY; IMMUNOFLUORESCENCE; IMMUNOSUPPRESSIVE TREATMENT; LIVER; LUNG; MORPHOMETRICS; MOUSE; NONHUMAN; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; SALIVARY GLAND; SPLEEN; TRANSPLANT ARTERIOSCLEROSIS; VIRUS LOAD; VIRUS STRAIN;

ANIMALS; AORTA, ABDOMINAL; ARTERIOSCLEROSIS; CYTOMEGALOVIRUS INFECTIONS; DNA PRIMERS; DNA PROBES; E-SELECTIN; GENES, MHC CLASS I; IMMUNOSUPPRESSIVE AGENTS; INTERCELLULAR ADHESION MOLECULE-1; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; MICE, INBRED STRAINS; RNA, MESSENGER; SIROLIMUS; TRANSPLANTATION, HOMOLOGOUS; VASCULAR CELL ADHESION MOLECULE-1;

EID: 77955984827     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181e8a699     Document Type: Article

References (34)

1. Taylor DO, Stehlik J, Edwards LB, et al. Registry of the international society for heart and lung transplantation: Twenty-sixth official adult heart transplant report-2009. J Heart Lung Transplant 2009; 28: 1007.
2. Mulligan MS, Shearon TH, Weill D, et al. Heart and lung transplantation in the United States, 1997-2006. Am J Transplant 2008; 8(4 pt 2): 977.
3. Weis M, von Scheidt W. Coronary artery disease in the transplanted heart. Annu Rev Med 2000; 51: 81.
4. Lietz K, Miller LW. Current understanding and management of allo-graft vasculopathy. Semin Thorac Cardiovasc Surg 2004; 16: 386.
5. Stassen FR, Vega-Cordova X, Vliegen I, et al. Immune activation following cytomegalovirus infection: More important than direct viral effects in cardiovascular disease? J Clin Virol 2006; 35: 349.
6. Valantine HA. The role of viruses in cardiac allograft vasculopathy. Am J Transplant 2004; 4: 169.
7. VamvakopoulosJ, HayryP.Cytomegalovirus and transplant arteriopa-thy: Evidence for a link is mounting, but the jury is still out. Transplantation 2003; 75: 742.
8. Potena L, Holweg CT, Chin C, et al. Acute rejection and cardiac allo-graft vascular disease is reduced by suppression of subclinical cytomeg-alovirus infection. Transplantation 2006; 82: 398.
9. Potena L, Grigioni F, Magnani G, et al. Prophylaxis versus preemptive anti-cytomegalovirus approach for prevention of allograft vasculopa-thy in heart transplant recipients. J Heart Lung Transplant 2009; 28: 461.
10. Bentz GL, Yurochko AD. Human CMV infection of endothelial cells induces an angiogenic response through viral binding to EGF receptor and beta1 and beta3 integrins.Proc Natl Acad Sci\USA 2008; 105: 5531.
11. Kronschnabl M, Stamminger T. Synergistic induction of intercellular adhesion molecule-1 by the human cytomegalovirus transactivators IE2p86 and pp71 is mediated via an Sp1-binding site. J Gen Virol 2003; 84(pt 1): 61.
12. Streblow DN, Soderberg-Naucler C, Vieira J, et al. The human cyto-megalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration. Cell 1999; 99: 511.
13. Bason C, Corrocher R, Lunardi C, et al. Interaction of antibodies against cytomegalovirus with heat-shock protein 60 in pathogenesis of atherosclerosis. Lancet 2003; 362: 1971.
14. Lemstrom KB, Bruning JH, Bruggeman CA, et al. Cytomegalovirus infection enhances smooth muscle cell proliferation and intimal thickening of rat aortic allografts. J Clin Invest 1993; 92: 549.
15. Morton DB, Griffiths PH. Guidelines on the recognition of pain, distress and discomfort in experimental animals and an hypothesis for assessment. VetRec 1985; 116: 431.
16. Koulack J, McAlister VC, Giacomantonio CA, et al. Development of a mouse aortic transplant model of chronic rejection. Microsurgery 1995; 16: 110.
17. Schleiss M, Eickhoff J, Auerochs S, et al. Protein kinase inhibitors of the quinazoline class exert anti-cytomegaloviral activity in vitro and in vivo. Antiviral Res 2008; 79: 49.
18. + T cells contribute to the development of transplant arteriosclerosis despite CD154 blockade. Transplantation 2000; 69: 2609.
19. Ensminger SM, Spriewald BM, Witzke O, et al. Kinetics of transplant arteriosclerosis in MHC-Class I mismatched and fully allogeneic mouse aortic allografts. Transplantation 2002; 73: 1068.
20. Overbergh L, Valckx D, Waer M, et al. Quantification of murine cytokine mRNAs using real time quantitative reverse transcriptase PCR. Cytokine 1999; 11: 305.
21. Nishiyama T, Mishima K, Obara K, et al. Amelioration of lacrimal gland inflammation by oral administration of K-13182 in Sjogren's syndrome model mice. Clin Exp Immunol 2007; 149: 586.
22. Yamamoto T, Nakahata Y, Tanaka M, et al. Acute physical stress elevates mouse period1 mRNA expression in mouse peripheral tissues via a glucocorticoid-responsive element. J Biol Chem 2005; 280: 42036.
23. Campbell AE, Cavanaugh VJ, Slater JS. The salivary glands as a privileged site of cytomegalovirus immune evasion and persistence. Med Microbiol Immunol 2008; 197:205.
24. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847.
25. Streblow DN, Kreklywich C, Yin Q, et al. Cytomegalovirus-mediated upregulation of chemokine expression correlates with the acceleration of chronic rejection in rat heart transplants. J Virol 2003; 77: 2182.
26. Soule JL, Streblow DN, Andoh TF, et al. Cytomegalovirus accelerates chronic allograft nephropathy in a rat renal transplant model with associated provocative chemokine profiles. Transplant Proc 2006; 38: 3214.
27. Hsich E, Zhou YF, Paigen B, et al. Cytomegalovirus infection increases development of atherosclerosis in Apolipoprotein-E knockout mice. Atherosclerosis 2001; 156: 23.
28. Vliegen I, Duijvestijn A, Grauls G, et al. Cytomegalovirus infection aggravates atherogenesis in apoE knockout mice by both local and systemic immune activation. Microbes Infect 2004; 6: 17.
29. Scalzo AA. Successful control of viruses by NK cells\A balance of opposing forces? Trends Microbiol 2002; 10: 470.
30. Streblow DN, Dumortier J, Moses AV, et al. Mechanisms of cytomegalovirus-accelerated vascular disease: Induction of paracrine factors that promote angiogenesis and wound healing. Curr Top MicrobiolIm-munol2008; 325: 397.
31. Kloover JS, Soots AP, Krogerus LA, et al. Rat cytomegalovirus infection in kidney allograft recipients is associated with increased expression of intracellular adhesion molecule-1 vascular adhesion molecule-1, and their ligands leukocyte function antigen-1 and very late antigen-4 in the graft. Transplantation 2000; 69: 2641.
32. Borst EM, Benkartek C, Messerle M. Use of bacterial artificial chromosomes in generating targeted mutations in human and mouse cytomegaloviruses. Curr Protoc Immunol 2007; Chapter 10: Unit 10 32.
33. Hu Y, Xu Q. Vessel graft atherosclerosis in murine models. Curr Drug Targets 2008; 9: 239.
34. Feig JE, Quick JS, Fisher EA. The role of a murine transplantation model of atherosclerosis regression in drug discovery. Curr Opin Inves-tigDrugs 2009; 10: 232.